Neuroprotection in traumatic brain injury: A complex struggle against the biology of nature

Current Opinion in Critical Care

Volumn 13, Issue 2, 2007, Pages 134-142

  Schouten, Joost W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trial; Head injury; Neuroprotection; Neurotrauma; Traumatic brain injury

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ANATIBANT; ANTICONVULSIVE AGENT; APTIGANEL; BLOOD CLOTTING FACTOR 7; BRADYKININ ANTAGONIST; CALPASTATIN; CYCLOSPORIN A; DELTIBANT; DEXAMETHASONE; DEXANABINOL; ELIPRODIL; ERYTHROPOIETIN; GLUTAMATE RECEPTOR ANTAGONIST; LUBELUZOLE; MAGNESIUM; MINOCYCLINE; NEUROPROTECTIVE AGENT; NIMODIPINE; OMEGA CONOTOXIN MVIIA; PRASTERONE; PROGESTERONE; STEROID; SUPEROXIDE DISMUTASE MACROGOL; TIRILAZAD; TRAXOPRODIL; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAS 203;

ABSENCE OF SIDE EFFECTS; CLINICAL EVALUATION; CLINICAL TRIAL; HUMAN; NEUROPROTECTION; PATHOPHYSIOLOGY; REVIEW; SEIZURE; STROKE; TRAUMATIC BRAIN INJURY;

BRADYKININ; BRAIN INJURIES; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; HUMANS; MAGNESIUM; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 33847323914     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3280895d5c     Document Type: Review

References (69)

1. Tagliaferri F, Compagnone C, Korsic M, et al. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148:255-268. This paper summarizes the current knowledge on the epidemiology of TBI in Europe and serves to highlight the lack of standardized data.
2. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 2006; 21:375-378.
3. Maas AI, Marmarou A, Murray GD, et al. Prognosis and clinical trial design in traumatic brain injury: the IMPACT* study. J Neurotrauma (in press).
4. Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury. J Neurotrauma (in press).
5. Graham DI, McIntosh TK, Maxwell WL, Nicoll JA. Recent advances in neurotrauma. J Neuropathol Exp Neurol 2000; 59:641-651.
6. Teasdale GM, Graham DI. Craniocerebral trauma: protection and retrieval of the neuronal population after injury. Neurosurgery 1998; 43:723-737.
7. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma 2002; 19:503-557.
8. Marklund N, Bakshi A, Castelbuono DJ, et al. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des 2006; 12:1645-1680. This is an excellent and extensive review of almost all preclinical research in TBI research.
9. Maas AI, Schouten JW, Teasdale GM. Neuroprotection. In: Reilly P, Bullock MR, editors. Head Injury. London: Hodder Arnold Publishers; 2005. pp. 406-440.
10. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharm 2006; 6:53-60.
11. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care 2004; 1:479-488.
12. Hoover RC, Motta M, Davis J, et al. Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma 2004; 21:501-512.
13. Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav 2005; 7 (Suppl 3):S25-S28.
14. Marmarou A, Nichols J, Burgess J, et al. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma 1999; 16:431-444.
15. Bailey I, Bell A, Gray J, et al. A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien) 1991; 110:97-105.
16. The European Study Group on Nimodipine in Severe Head Injury. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 1994; 80:797-804.
17. Harders A, Kakarieka A, Braakman R. Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group. J Neurosurg 1996; 85:82-89.
18. Morris GF, Bullock R, Marshall SB, et al. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg 1999; 91:737-743.
19. Young B, Runge JW, Waxman KS, et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 1996; 276:538-543.
20. Marshall LF, Maas AI, Marshall SB, et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 1998; 89:519-525.
21. Grumme T, Baethmann A, Kolodziejczyk D, et al. Treatment of patients with severe head injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases. Res Exp Med (Berl) 1995; 195:217-229.
22. Gaab MR, Trost HA, Alcantara A, et al. 'Ultrahigh' dexamethasone in acute brain injury. Results from a prospective randomized double-blind multicenter trial (GUDHIS). German Ultrahigh Dexamethasone Head Injury Study Group. Zentralbl Neurochir 1994; 55:135-143.
23. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364:1321-1328.
24. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365:1957-1959.
25. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006; 97:1611-1626.
26. Yurkewicz L, Weaver J, Bullock MR, Marshall LF. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 2005; 22:1428-1443.
27. Maas AI, Murray G, Henney H 3rd, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006; 5:38-45. This paper reports the results of one of the most recent phase III trials in TBI; this is the first trial in TBI to use the sliding-dichotomy approach to improve outcome analysis.
28. Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev 2004; 1:CD003986.
29. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6:53-60.
30. Bareyre FM, Saatman KE, Raghupathi R, McIntosh TK. Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats. J Neurotrauma 2000; 17:1029-1039.
31. van den Heuvel C, Vink R. The role of magnesium in traumatic brain injury. Clin Calcium 2004; 14:9-14.
32. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomized controlled trial. Lancet Neurol 2007; 6:29-38. This paper reports results of a single-center phase III trial of magnesium in TBI. In contrast to general belief the results show that magnesium is not effective and may even have harmful effects.
33. Muir KW, Lees KR, Ford I, et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004; 363:439-445.
34. McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med 2005; 33:661-666.
35. McKee JA, Brewer RP, Macy GE, et al. Magnesium neuroprotection is limited in humans with acute brain injury. Neurocrit Care 2005; 2:342-351.
36. Sakamoto T, Takasu A, Saitoh D, et al. Ionized magnesium in the cerebrospinal fluid of patients with head injuries. J Trauma 2005; 58:1103-1109.
37. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res 2005; 79:231-239.
38. Merenda A, Bullock R. Clinical treatments for mitochondrial dysfunctions after brain injury. Curr Opin Crit Care 2006; 12:90-96. Recent review on the central role of mitochondria in the pathophysiology of TBI.
39. Mazzeo AT, Kunene NK, Gilman CB, et al. Severe human traumatic brain injury, but not cyclosporin A treatment, depresses activated T lymphocytes early after injury. J Neurotrauma 2006; 23:962-975.
40. Empey PE, McNamara PJ, Young B, et al. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma 2006; 23:109-116.
41. Lee LL, Galo E, Lyeth BG, et al. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp Neurol 2004; 190:70-78.
42. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential therapeutic exploitation in brain disease. J Neurosurg Anesth 2006; 18:132-138.
43. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005; 19:1701-1703.
44. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
45. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005; 61:189-195.
46. Mushkudiani N, Engel DC, Steyerberg EW, et al. The prognostic value of demographic characteristics in traumatic brain injury: results from the IMPACT* study. J Neurotrauma (in press).
47. Stein DG, Hoffman SW. Estrogen and progesterone as neuroprotective agents in the treatment of acute brain injuries. Pediatr Rehabil 2003; 6:13-22.
48. Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005; 1049:112-119.
49. Robertson CL, Puskar A, Hoffman GE, et al. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp Neurol 2006; 197:235-243.
50. He J, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci 2004; 22:19-31.
51. Djebaili M, Guo Q, Pettus EH, et al. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005; 22:106-118.
52. Wright DW, Ritchie JC, Mullins RE, et al. Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J Clin Pharmacol 2005; 45:640-648.
53. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2006 [epub ahead of print].
54. Marmarou A, Guy M, Murphey L, et al. A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J Neurotrauma 2005; 22:1444-1455.
55. Wada K, Chatzipanteli K, Busto R, Dietrich WD. Role of nitric oxide in traumatic brain injury in the rat. J Neurosurg 1998; 89:807-818.
56. Cherian L, Hlatky R, Robertson CS. Nitric oxide in traumatic brain injury. Brain Pathol 2004; 14:195-201.
57. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005; 76:126-152.
58. Clark RSB, Kochanek PM, Obrist WD, et al. Cerebrospinal fluid and plasma nitrite and nitrate concentrations after head injury in humans. Crit Care Med 1996; 24:1243-1251.
59. Pou S, Pou WS, Bredt DS, et al. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992; 267:24173-24176.
60. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric-oxide synthases. J Biol Chem 2001; 276:14533-14536.
61. Gahm C, Holmin S, Wiklund PN, et al. Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion. J Neurotrauma 2006; 23:1343-1354.
62. Werner ER, Schmidt HH. Nitric oxide synthase inhibitors: pterin antagonists and antipterins. In Handbook of experimental pharmacology. Berlin: Springer Verlag; 2000: pp.137-157.
63. Morales DM, Marklund M, Lebold D, et al. Experimental models of traumatic brain injury: do we really need to build a better mousetrap? Neuroscience 2005; 136:971-989.
64. Doppenberg EM, Choi SC, Bullock R. Clinical trials in traumatic brain injury: lessons for the future. J Neurosurg Anesthesiol 2004; 16:87-94.
65. Hillered L, Persson L, Nilsson P, et al. Continuous monitoring of cerebral metabolism in traumatic brain injury: a focus on cerebral microdialysis. Curr Opin Crit Care 2006; 12:112-118.
66. Wang KK, Larner SF, Robinson G, Hayes RL. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol 2006; 19:514-519. This is a brief review with the same topic as the current review. There is some overlap in the drugs discussed, some points of view are different.
67. Murray GD, Barer D, Choi S, et al. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005; 22:511-517.
68. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344:556-563.
69. Hukkelhoven CW, Steyerberg EW, Farace E, et al. Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials. J Neurosurg 2002; 97:549-557.